PreciseDx is at the forefront of personalized medicine, particularly in the realm of breast cancer treatment, utilizing advanced artificial intelligence to enhance patient care. The company specializes in cancer risk stratification, providing patient-specific risk information through the analysis of morphological features. This innovative approach allows clinical teams to gain actionable insights that inform treatment decisions, ultimately leading to improved patient outcomes. By integrating AI with lab processes and workflow systems, PreciseDx transforms clinical modeling, patient phenotyping, and image analysis, thereby supporting pathologists and oncologists in delivering precise and individualized treatment plans.

The AI-powered predictive platform developed by PreciseDx creates disease-specific assays that yield detailed patient risk profiles. This technology not only enhances diagnostic precision but also reduces error rates and costs for healthcare providers and payers alike. Furthermore, the platform is designed to support biopharmaceutical research and development, enabling researchers to utilize AI insights derived from extensive, well-annotated study populations. By focusing on delivering better data and outcomes, PreciseDx is committed to advancing the field of oncology and improving the overall healthcare continuum for patients, providers, and payers.

United States

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

PreciseDx

Company Details